Drug Information

Drug General Information
Drug ID
D03WQS
Former ID
DCL000358
Drug Name
BMS-582664
Synonyms
Brivanib alaninate; BMS 582664; BMS582664; BMS-582664, Brivanib alaninate; Brivanib alaninate (INN/USAN); L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-f)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester
Drug Type
Small molecular drug
Indication Hepatocellular carcinoma [ICD9: 155; ICD10:C22.0] Phase 3 [522676], [542969]
Therapeutic Class
Anticancer Agents
Company
Bristol Myers Squibb
Structure
Download
2D MOL

3D MOL
Formula
C22H24FN5O4
InChI
InChI=1S/C22H24FN5O4/c1-11-7-15-16(27-11)5-6-17(19(15)23)32-21-20-13(3)18(8-28(20)26-10-25-21)30-9-12(2)31-22(29)14(4)24/h5-8,10,12,14,27H,9,24H2,1-4H3/t12-,14+/m1/s1
InChIKey
LTEJRLHKIYCEOX-OCCSQVGLSA-N
CAS Number
CAS 649735-63-7
PubChem Compound ID
11154925
PubChem Substance ID
16233765, 24458858, 42209717, 77346692, 92309407, 96025561, 99436997, 103577780, 124757026, 125163830, 126661322, 126680119, 126729215, 131480766, 135195809, 136340217, 136367326, 136920388, 142629726, 152258180, 160647016, 162011762, 162037460, 164837130, 174530181, 180423171, 184816560, 198987707, 223677760, 226799738, 248925490, 249565777, 252160520, 252438464, 252543406
Target and Pathway
Target(s) FGF-3 receptor Target Info Inhibitor [536474]
KEGG Pathway MAPK signaling pathway
Ras signaling pathway
Rap1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Signaling pathways regulating pluripotency of stem cells
Regulation of actin cytoskeleton
Pathways in cancer
MicroRNAs in cancer
Bladder cancer
Central carbon metabolism in cancer
PANTHER Pathway FGF signaling pathway
Reactome FGFR3 mutant receptor activation
WikiPathways Regulation of Actin Cytoskeleton
Endochondral Ossification
Bladder Cancer
Neural Crest Differentiation
Signaling by FGFR
References
Ref 522676ClinicalTrials.gov (NCT00908752) Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC. U.S. National Institutes of Health.
Ref 542969(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8097).
Ref 536474A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.